A phase II study of irinotecan plus chronomodulated oxaliplatin, 5-fluorouracil and folinic acid in advanced colorectal cancer patients

por Garufi, C, Bria, E, Vanni, B, Zappalà, A M R, Sperduti, I, Terzoli, E
Publicado 2003

Immunological effects of alternative weekly interferon-alpha-2b and low dose interleukin-2 in patients with cancer.

por Fiorentino, B., Di Stefano, P., Giuliani, C., Amatetti, C., Tinari, N., Natoli, C., Garufi, C., Iacobelli, S.
Publicado 1992

Dynamic test with recombinant interferon-alpha-2b: effect on 90K and other tumour-associated antigens in cancer patients without evidence of disease.

por Natoli, C., Garufi, C., Tinari, N., D'Egidio, M., Lesti, G., Gaspari, L. A., Visini, R., Iacobelli, S.
Publicado 1993

Circadian optimisation of irinotecan and oxaliplatin efficacy in mice with Glasgow osteosarcoma

por Granda, T G, D'Attino, R-M, Filipski, E, Vrignaud, P, Garufi, C, Terzoli, E, Bissery, M-C, Lévi, F
Publicado 2002

Cetuximab plus chronomodulated irinotecan, 5-fluorouracil, leucovorin and oxaliplatin as neoadjuvant chemotherapy in colorectal liver metastases: POCHER trial

por Garufi, C, Torsello, A, Tumolo, S, Ettorre, G M, Zeuli, M, Campanella, C, Vennarecci, G, Mottolese, M, Sperduti, I, Cognetti, F
Publicado 2010